LRG1’s role in diabetic kidney disease and kidney fibrosis
Official title: The Role of LRG1 in Diabetic Kidney Disease
Funded at Icahn School of Medicine at Mount Sinai · NIH-11466076 · Data updated 2026-11-12
A study examines how a specific protein, LRG1, influences kidney disease related to diabetes and its scarring, with the aim of finding targeted ways to slow or prevent damage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 1, 2018 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $892,332 |
| NIH project number | 2R01DK117913-06A1 |
| Project ID | NIH-11466076 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with diabetes who are at risk of or have diabetic kidney disease may be eligible, depending on study design specifics.
✕Less likely to help
Some participants may not directly benefit if their disease does not involve the targeted pathways or if outcomes depend on later-stage interventions.
What this research studies
This project looks at how the protein LRG1 modifies TGF-β signaling, which is linked to kidney scarring in diabetic kidney disease. Researchers plan to explore mechanisms in DKD to identify points where therapy could dampen harmful signaling without causing broad side effects. The work builds on prior findings that LRG1 affects the pathways driving fibrosis and aims to translate those insights into safer, more precise interventions. The study is conducted at Icahn School of Medicine at Mount Sinai under the guidance of Kyung Lee, focusing on kidney disease in adults with diabetes.
Why it matters
Potential benefit: If successful, the research could lead to targeted treatments that reduce kidney scarring and slow progression to kidney failure in people with diabetic kidney disease.
How similar studies have gone: Previous work suggests LRG1 modulates TGF-β signaling in DKD, but precise, safe modulation strategies are still under investigation.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Lee, Kyung — Icahn School of Medicine at Mount Sinai
- Study coordinator: Lee, Kyung
Related research
Other NIH-funded projects on the same topics.
-
siRNA nanoparticle treatment to stop diabetic kidney damage
A new nanoparticle-delivered gene-silencing treatment aims to lower kidney inflammation in people with diabetes to help protect their kidneys.
-
Genetic discovery for diabetic kidney disease in adults
A scientist team is studying the genes that influence diabetic kidney disease in adults to better understand why some people develop it.
-
Non-canonical NF-kB and inflammation in diabetic kidney disease
A study to understand how a specific inflammatory pathway worsens kidney disease in adults with type 2 diabetes and how it might be treated.
-
Epidermal microfluidic screen to detect diabetic kidney disease
A new skin-based microfluidic test platform may help identify kidney complications in people with diabetes using real-time biomarkers from sweat and glucose data.
-
PFAS exposure and kidney disease risk in teens with type 2 diabetes
Aging and kidney health study in youths with type 2 diabetes to see how a common chemical (PFAS) affects kidney risk and how to prevent or treat it.
-
GSK3beta’s role in diabetic kidney disease and protecting kidney cells
This grant looks at how a molecule called GSK3beta affects kidney damage in people with diabetes and whether targeting it can protect kidney cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.